Shire: Proving the Specialty Model
Executive Summary
As generics circle over Adderall XR, Shire's management must prove that the firm's original "search & development" model can still work.
You may also be interested in...
Shire: Remodeling Specialty Pharma
As biotech and Big Pharma invade spec pharma's traditional in-licensing ground, Shire's challenge is to bring investors along with its necessary strategic evolution. They've succeeded so far. Other spec pharma firms should take note of how.
Cephalon: Can Spec Pharma do R&D?
Cephalon's 2005 dealmaking flurry illustrates the growing influence of in-house R&D on a firm whose success to date has come from in-licensing. Its challenge will be selling investors pipeline potential, as well as earnings growth.
Shire/TKT: The Price of Diversification
Shire's proposed $1.6 billion cash takeover of TKT answers investors' call for some deal-making action and pipeline diversification. But critics say Shire has paid over the odds for some risky programs in unfamiliar territory--rather like it did with BioChem.